Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)

This study has been completed.
Sponsor:
Information provided by:
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00358306
First received: July 28, 2006
Last updated: February 16, 2010
Last verified: February 2010
  Purpose

To understand how AKI (Acute Kidney Injury) leads to chronic kidney disease so therapies can be found to alter the progression of events thereby significantly impacting the long-term outcomes of children who develop AKI.


Condition
Acute Renal Failure
Chronic Kidney Failure
Endothelial Dysfunction
Hemolytic-uremic Syndrome (HUS)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Enrollment: 36
Study Start Date: April 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
a
those with previous history of Acute kidney injury

Detailed Description:

This research study is designed to study what happens to the kidneys after they have an injury. There is some evidence that even if there appears to be great improvement of kidney function, an injury can put patients at risk for long-term problems with their kidney function and increase their risk to have high blood pressure. We want to collect information from participants to help explain why this injury can cause future problems, including Chronic Kidney Disease (CKD) which may help us prevent these health problems.

  Eligibility

Ages Eligible for Study:   2 Years to 20 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Children 2-20 years old with history of acute kidney injury

Criteria

Inclusion Criteria:

  • Children between age 2-20
  • Decrease in renal function by 25% or greater
  • Renal function has returned to normal

Exclusion Criteria:

  • History of chronic disease
  • Cancer
  • Congenital heart disease
  • Organ Transplantation
  • Liver disease
  • Pulmonary disease
  • Diabetes other primary metabolic condition
  • Severe neurologic impairments
  • Hypertension
  • Auto-immune
  • Infectious disease or renal disease
  • Smokers
  • Renal disease w/primary cause i.e. - HUS or Glomerulonephritis
  • severe allergies including allergy to seafood and/or iodine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00358306

Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Principal Investigator: David Askenazi, MD UAB Pediatric Nephrology
  More Information

No publications provided

Responsible Party: David Askenazi M.D., UAB
ClinicalTrials.gov Identifier: NCT00358306     History of Changes
Other Study ID Numbers: F070309010
Study First Received: July 28, 2006
Last Updated: February 16, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of Alabama at Birmingham:
Endothelium
Chronic Kidney Disease
Acute Kidney Injury
Hemolytic-uremic syndrome (HUS)

Additional relevant MeSH terms:
Acute Kidney Injury
Hemolytic-Uremic Syndrome
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency
Renal Insufficiency, Chronic
Syndrome
Anemia
Anemia, Hemolytic
Blood Platelet Disorders
Disease
Hematologic Diseases
Pathologic Processes
Thrombocytopenia
Thrombotic Microangiopathies
Uremia
Urologic Diseases

ClinicalTrials.gov processed this record on November 25, 2014